China SXT Pharmaceuticals Inc. [SXTC] Revenue clocked in at $1.90 million, down -63.40% YTD: What’s Next?

Related

Share

China SXT Pharmaceuticals Inc. [NASDAQ: SXTC] stock went on an upward path that rose over 11.63% on Wednesday, amounting to a one-week price increase of more than 12.26%. The company report on March 14, 2022 that China SXT Pharmaceuticals, Inc. Enters into Securities Purchase Agreement to Issue a 6% Convertible Promissory Note in the Original Principal Amount of $2.8 Million.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored


China SXT Pharmaceuticals, Inc. (“SXTC” or the “Company”), (NASDAQ: SXTC), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces (“TCMPs”), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements (“TCMHS”), today announced that it entered into a securities purchase agreement to issue a convertible promissory note in the original principal amount of $2,804,848.00 to Streeterville Capital, LLC, a Utah limited liability company.

The 12-month note shall bear interest at the rate of 6% per annum. Any time after ninety (90) days of issuance, the investor may elect to convert all or any portion of the note at a fixed conversion price, initially $0.30. Any time after ninety (90) days of issuance, all or any portion of the note may be convertible into ordinary shares of SXTC at a redemption conversion price of the lower of (i) the Lender Conversion Price which is initially $0.30 and (ii)80% of the average of the lowest VWAP during the fifteen (15) trading days immediately preceding the conversion notice is delivered, subject to monthly conversion limitation of $600,000. The investor shall not sell more than 15% of the weekly trading volume in any given week in the open market so long as there is no event of default. The Company intends to use the net proceeds from this offering for general corporate purposes, including, but not limited to, working capital and other business opportunities.

Over the last 12 months, SXTC stock dropped by -86.55%.

The market cap for the stock reached $13.37 million, with 15.55 million shares outstanding and 14.49 million shares in the current float. Compared to the average trading volume of 6.35M shares, SXTC stock reached a trading volume of 5901013 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Guru’s Opinion on China SXT Pharmaceuticals Inc. [SXTC]:

The Average True Range (ATR) for China SXT Pharmaceuticals Inc. is set at 0.03, with the Price to Sales ratio for SXTC stock in the period of the last 12 months amounting to 7.03. The Price to Book ratio for the last quarter was 0.27, with the Price to Cash per share for the same quarter was set at 0.00.

SXTC Stock Performance Analysis:

China SXT Pharmaceuticals Inc. [SXTC] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 12.26. With this latest performance, SXTC shares gained by 44.24% in over the last four-week period, additionally sinking by -77.12% over the last 6 months – not to mention a drop of -86.55% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SXTC stock in for the last two-week period is set at 56.27, with the RSI for the last a single of trading hit 63.35, and the three-weeks RSI is set at 50.24 for China SXT Pharmaceuticals Inc. [SXTC]. The present Moving Average for the last 50 days of trading for this stock 0.2194, while it was recorded at 0.2142 for the last single week of trading, and 0.8413 for the last 200 days.

Insight into China SXT Pharmaceuticals Inc. Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and China SXT Pharmaceuticals Inc. [SXTC] shares currently have an operating margin of -36.18 and a Gross Margin at +59.43. China SXT Pharmaceuticals Inc.’s Net Margin is presently recorded at -57.52.

Return on Total Capital for SXTC is now -10.76, given the latest momentum, and Return on Invested Capital for the company is -21.63. Return on Equity for this stock declined to -21.67, with Return on Assets sitting at -9.77. When it comes to the capital structure of this company, China SXT Pharmaceuticals Inc. [SXTC] has a Total Debt to Total Equity ratio set at 0.27. Additionally, SXTC Total Debt to Total Capital is recorded at 0.27, with Total Debt to Total Assets ending up at 0.13. Long-Term Debt to Equity for the company is recorded at 0.04, with the Long-Term Debt to Total Capital now at 0.04.

Reflecting on the efficiency of the workforce at the company, China SXT Pharmaceuticals Inc. [SXTC] managed to generate an average of -$28,627 per employee. Receivables Turnover for the company is 0.52 with a Total Asset Turnover recorded at a value of 0.17.China SXT Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.20 and a Current Ratio set at 1.30.

China SXT Pharmaceuticals Inc. [SXTC] Insider Position Details

There are presently around $0 million, or 1.60% of SXTC stock, in the hands of institutional investors. The top three institutional holders of SXTC stocks are: SUSQUEHANNA INTERNATIONAL GROUP, LLP with ownership of 254,283, which is approximately New of the company’s market cap and around 12.11% of the total institutional ownership; VIRTU FINANCIAL LLC, holding 42,993 shares of the stock with an approximate value of $9000.0 in SXTC stocks shares; and GEODE CAPITAL MANAGEMENT, LLC, currently with $6000.0 in SXTC stock with ownership of nearly 0% of the company’s market capitalization.

6 institutional holders increased their position in China SXT Pharmaceuticals Inc. [NASDAQ:SXTC] by around 323,118 shares. Additionally, 5 investors decreased positions by around 110,258 shares, while 1 investors held positions by with 26,851 shares. The mentioned changes placed institutional holdings at 406,525 shares, according to the latest SEC report filing. SXTC stock had 4 new institutional investments in for a total of 314,696 shares, while 4 institutional investors sold positions of 108,999 shares during the same period.

[class^="wpforms-"]
[class^="wpforms-"]